Navigation Links
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
Date:9/30/2008

e Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (SEC) or an applicable exemption from the registration requirements. Micromet, Inc. has agreed to file a registration statement with respect to the shares within 30 calendar days after the closing date. This news release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293
'/>"/>

SOURCE Micromet, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
2. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
3. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
5. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
6. Micromet to Present at Two Upcoming Investor Conferences
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
9. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
10. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 Reports from ... United States suffer from one or more chronic health ... cancer. Medication can address some of these diseases, but ... that many sufferers face. While implanted nerve stimulation devices ... the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the ... grow moderately through 2023 as the aging population, increasing ... dental biomaterials all spur procedure volumes. Growth will be ... China and India , ... reach for a larger proportion of the population. ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Based ... the overall surgical imaging market is dominated by ... the surgical imaging market. These players include GE ... Ziehm Imaging (Germany). , Full Report Copy ... of GE Healthcare can be attributed to its ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... Global Quartz Tubing industry. For an overview analysis, ... classification, application, industry chain structure, industry overview, policy ... quartz tubing industry has witnessed rapid development ... number of acquisitions. This report mentions quartz tubing ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 42020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... , LONDON, November 18 ... the Disease , - An Estimated Two Billion Work ... report issued today reveals for the first time that,people between the ages of ... Education for Health and other leading experts, the,report uncovers a new, younger majority ...
... ... Sonitor,s Ultrasound identification (USID) technology is now including Wi-Fi to enable the ultimate hospital ... , ... November 18, 2009 -- One of the many advantages of Sonitor,s recently released High ...
... among historians, journalists and politicians, and has been recounted everywhere ... British forces used chemical weapons on Iraqis just after World ... fully squared with the historical record, says R. M. Douglas, ... in the December issue of The Journal of Modern ...
Cached Biology Technology:Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 2Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 3Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD) 4Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 2Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 3Hand-washing Compliance, Computer Auto Log-on/ Log-off and Patient Fall-detection are Enabled by Real Time Location System (RTLS) with Sub-room Location Accuracy 4Despite claims, UK did not gas Iraqis in the 1920s, new research finds 2Despite claims, UK did not gas Iraqis in the 1920s, new research finds 3Despite claims, UK did not gas Iraqis in the 1920s, new research finds 4
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... 18 announcement that only 25 to 34 of the Amur ... wild, World Wildlife Fund says the number must now be ... Anonymous tips led officers of two leopard anti-poaching squads to ... miles from Bamburovo village within the watershed of Alimovka River ...
... and the bees. But apparently when it comes to birds, ... the difference is genetic. Species with differentiated sex chromosomes (X ... that males and females get different-sized portions of sex chromosome ... But research published today in the Journal of Biology shows ...
... that low birthweight babies born with low sodium (salt) in ... sodium later in life. In the study, researchers also ... sodium blood serum consumed ~1700 mg more sodium per day ... These data, taken together with other recent findings, make it ...
Cached Biology News:Bird sex is something else 2Like salty food? Chances are you had low blood sodium when you were born 2Like salty food? Chances are you had low blood sodium when you were born 3
... Product Rabbit polyclonal to JNK1 ... peptide mapping to an internal domain containing phosphorylated ... Human, Mouse and Rat. Not yet tested in ... consist of several subgroups, including the ERK, JNK, ...
... potent Rnase free Ribonuclease Inhibitor ... broad range of temperatures and ... not inhibit SP6, T7, or ... M-MLV reverse transcriptase or Taq ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... All the functionality of the micro1401 but ... and more available channels of waveform input ... option for programmable front-end gain. Can be ... waveform inputs and from 4 to 8 ...
Biology Products: